The Toronto-based life sciences company is currently advancing CardiolRx, a small-molecule drug candidate designed to modulate the inflammasome pathway. This mechanism is central to treating inflammation and fibrosis linked to conditions like pericarditis, myocarditis, and heart failure. The firm’s clinical focus is highlighted by the MAVERIC program, which includes an ongoing pivotal Phase III trial for recurrent pericarditis—a condition that often leaves patients with debilitating chest pain and reduced quality of life.
Cardiol Therapeutics to Discuss Heart Disease Pipeline in Boston
Cardiol Therapeutics will present its latest progress in anti-inflammatory heart disease treatments during a fireside chat at Canaccord Genuity’s 46th Annual Growth Conference. The session is scheduled for August 11, 2026, at 9:00 a.m. EDT at the InterContinental Boston Hotel, offering investors insight into the firm's clinical pipeline.
Beyond the MAVERIC program, the company is evaluating the safety and efficacy of its therapies in treating acute myocarditis and is developing CRD-38, a subcutaneous formulation aimed at heart failure. Given that heart failure remains a primary driver of hospitalization and healthcare costs in the United States, the upcoming presentation in Boston serves as a platform for the firm to detail its strategy for navigating these complex therapeutic markets. A live webcast of the discussion will be available on the investor relations section of the company website.
Comments (0)
No comments yet. Be the first!